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Abstract
Background: We aimed to investigate the prevalence and predictors of Complementary and Alternative Medicine
(CAM) use among cancer patients and non-cancer volunteers, and to assess the knowledge of and attitudes
toward CAM use in oncology among health care professionals.
Methods: This is a cross-sectional questionnaire survey conducted in a single institution in Ireland. Survey was
performed in outpatient and inpatient settings involving cancer patients and non-cancer volunteers. Clinicians and
allied health care professionals were asked to complete a different questionnaire.
Results: In 676 participants including 219 cancer patients; 301 non-cancer volunteers and 156 health care
professionals, the overall prevalence of CAM use was 32.5% (29.1%, 30.9% and 39.7% respectively in the three study
cohorts). Female gender (p < 0.001), younger age (p = 0.004), higher educational background (p < 0.001), higher
annual household income (p = 0.001), private health insurance (p = 0.001) and non-Christian (p < 0.001) were
factors associated with more likely CAM use. Multivariate analysis identified female gender (p < 0.001), non-
Christian (p = 0.001) and private health insurance (p = 0.015) as independent predictors of CAM use. Most health
care professionals thought they did not have adequate knowledge (58.8%) nor were up to date with the best
evidence (79.2%) on CAM use in oncology. Health care professionals who used CAM were more likely to
recommend it to patients (p < 0.001).
Conclusions: This study demonstrates a similarly high prevalence of CAM use among oncology health care
professionals, cancer and non cancer patients. Patients are more likely to disclose CAM usage if they are specifically
asked. Health care professionals are interested to learn more about various CAM therapies and have poor
evidence-based knowledge on specific oncology treatments. There is a need for further training to meet to the
escalation of CAM use among patients and to raise awareness of potential benefits and risks associated with these
therapies.
Background
Complementary and Alternative Medicine (CAM) is ‘a
comprehensive term used to refer both to traditional
medical systems such as traditional Chinese medicine,
Indian ayurveda and Arabic unani medicine, and to var-
ious forms of indigenous medicine’ [1]. The use of
CAM has gained enormous popularity among the gen-
eral public and numerous surveys have reported particu-
larly high prevalence of use in cancer patients [2-5].
Previous studies demonstrated that patients were using
CAM without obtaining enough information regarding
these therapies [5]. Documented figures of up to 60% of
these patients did not disclose their CAM usage to the
doctors, and most cited reason was that their doctors
did not ask them [4,5]. These findings highlighted the
lack of awareness of CAM usage among health care pro-
fessionals. This could have important oncologic implica-
tions due to potential drug-herb-vitamin interactions.
For example, shark cartilage has been found to have no
effect on tumour growth in clinical trials, but caused
severe gastrointestinal toxicity [6,7]. More importantly,
St. John’s Wort was associated with significantly reduced
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motherapeutic agent, Irinotecan [8]. The majority of
novel anticancer treatments are studied in advanced
cancer patients and this cohort has been shown to use
CAM more frequently [9]. This can be a confounding
factor potentially leading to under- or over-estimated
drug levels, toxicity, side effect profiles, drug-herb-vita-
min interactions and unreliable clinical trial data [10].
Previous surveys in cancer patients have mainly
focused on the prevalence and predictors of CAM usage
[2-5,9]. In Ireland, the prevalence of CAM use in oncol-
ogy has been reported in a selected cohort of patients
with head and neck cancer [11]. Few studies have
assessed the attitudes and perceptions of health care
professionals toward CAM use in oncology. Richardson
et al reported negative perceptions on CAM by clinical
oncologists and Hyodo et al reported discrepant views
on CAM between oncologist and cancer patients
[12,13]. Risberg et al investigated oncology professionals’
knowledge of and attitudes toward CAM in a group of
oncologists, nurses, clerks and interventional radiogra-
phers [14]. However, the study cohorts did not represent
all the members of the current multidisciplinary team.
Furthermore, these studies did not assess patients and
health care professionals’ attitudes and perceptions
simultaneously [13,14], which may enable better under-
standing of the interactions between the two parties.
Lastly, health care professionals’ knowledge of the use of
CAM therapies in specific cancer-related clinical condi-
tions has not previously been investigated.
The aims of this study were therefore to a) investigate
the interest and prevalence of CAM use among cancer
patients attending a tertiary referral centre in Ireland; b)
determine factors associated with CAM usage; (c) assess
communications between health care professionals and
patients by obtaining opinions and experience from
both parties; and (d) investigate health care profes-
sionals’ knowledge of and attitudes toward CAM.
Methods
Participants
This was a single centre cross-sectional survey. Partici-
pants were recruited between July and August 2008.
Three study cohorts were included in this study, namely
cancer patients, non-cancer volunteers and health care
professionals. The study was granted approval by the
Clinical Research Ethics Committee of the University
College Hospital Galway. Patients and volunteers were
accrued after explanation of the nature of the survey
both in verbal and written format, followed by verbal
consent. Cancer patients and non-cancer volunteers
were identified from the outpatient clinics, inpatient
wards, oncology day ward and radiotherapy department.
Cancer patients were patients who have been diagnosed
with any cancer in the past. Non-cancer volunteers were
patients who were on the wards or attending outpatient
clinic for reasons other than cancer, or visitors. Thirty-
six consultants across 13 specialties (breast and endo-
crine surgery; general and gastrointestinal surgery; plas-
tics and reconstructive surgery; urology; head and neck
surgery; obstetrics and gynaecology; medical oncology;
radiation oncology; dermatology; respiratory medicine;
palliative medicine; neurology and haematology) gave
permission to have their patients recruited in this study.
The study was coordinated by a postgraduate researcher
and a medical student undertaking summer research
project. Nurses at each study location assisted with the
accrual process.
Health care professionals consisted of doctors, nurses,
physiotherapists, pharmacists, speech and language, and
occupational therapists. All of these health care profes-
sionals are involved in the care of cancer patients. Doc-
tors and nurses were asked to complete the
questionnaire at various locations within the hospital.
For other allied health care professionals, questionnaires
were distributed to the corresponding departments.
Questionnaires
We utilised a modified version of a previously published
questionnaire validated in Japan [5]. Prior to the com-
mencement of the survey, the questionnaire was distribu-
ted to all participating consultants for review. The
structure was further modified and questions reworded
according to consultants’ feedback. The anonymised ques-
tionnaire collected data on sociodemographics; use of
CAM and specific details such as types of CAM, expecta-
tions and reasons for use; cancer-related characteristics
and treatment (additional files 1 and 2). The questionnaire
also incorporated Hospital Anxiety and Depression Scale
(HADS) which is a validated brief 14-item scoring system
to assess emotional state [15]. Data was also collected on
the location of consultation, stage of cancer and a simpli-
fied Karnofsky performance status score.
The questionnaire distributed to health care profes-
sionals was composed of questions regarding their spe-
cialties and positions; use of CAM; attitudes towards
CAM and previous experience during consultations.
Five quiz-like questions regarding the use of CAM in
specific cancer-related scenarios were incorporated to
determine if health care professionals were up to date
with the best available evidence (additional files 1 and
2). The ‘correct’ answers to these questions were based
on level 1a evidence [16-20].
Statistical Analysis
Statistical analysis was performed using SPSS 15.0 soft-
ware (Chicago, IL, USA). Univariate comparison of vari-
ables was assessed using c
2 test for nominal or ordinal
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used for parametric and non-parametric continuous
data respectively. Multivariate analysis was performed
using binary logistic regression with forward conditional
method. Variables that were significant on univariate
analyses were entered into the regression model. A p
value of less than 0.05 was considered statistically signif-
icant for all tests.
Results
Characteristics of Participants
A total of 728 participants were asked to complete the
questionnaire, 52 were excluded from subsequent analy-
sis as 5 were erroneously filled out by clerical staff and
47 had excessive missing information. Therefore, 676
questionnaires were valid for analysis including 301
completed by non-cancer volunteers, 219 by cancer
patients and 156 by health care professionals. The
majority of participants were Caucasians. Nineteen dif-
ferent malignancies were represented in the cancer
patient cohort. The prevalence of CAM use among can-
cer patients, non-cancer volunteers and health care pro-
fessionals were 29.1%, 30.9% and 39.7% respectively. The
prevalence rate in the entire study cohort was 32.5%.
Characteristics of cancer patients and non-cancer volun-
teers are summarised in Table 1, and characteristics of
health care professionals are summarised in Table 2.
Types of CAM Use
Biologically-based and orally ingested CAM such as nat-
ural supplements (i.e. Probiotics, fish oil, flax seeds, mel-
atonin, etc.), vitamins, green tea and herbal or folk
remedies (i.e. garlic, ginger, Essiac, aloe vera, ginseng,
Laetrile, etc.) were the most commonly used CAM in
the study cohorts. Manipulative and body-based prac-
tices such as massage therapy, acupuncture, yoga and
chiropractic therapy were popular among CAM users.
Energy medicine (i.e. energy healing, biofeedback, etc.),
mind-body medicine (i.e. psychotherapy, meditation,
etc.) and whole medical systems such as homeopathy
and traditional Chinese medicine were less commonly
used. The types of CAM used in our study cohorts are
summarised in Table 3.
Predictors of CAM Use
On univariate analysis, female gender (p < 0.001),
younger age (p = 0.004), higher educational background
(p < 0.001), higher annual household income (p =
0.001), private health care insurance (p = 0.001), non-
Christian (p < 0.001) were found to be factors associated
with more likely CAM usage. No association was found
between ethnicity, HADS and CAM use (Table 1). Mul-
tivariate analysis identified female gender (p < 0.001),
non-Christian (p = 0.001) and private health care
insurance (p = 0.015) as independent predictive factors
of CAM use (Table 4).
In the cancer patient cohort, patients who received
hormonal therapy were more likely to use CAM (p =
0.016). Interestingly, no association was found between
CAM use and cancer stage, and Karnofsky performance
status score.
Attitudes and Perceptions Toward CAM
Among 155 CAM users, reasons for using CAM were:
72 (51.1%) recommended by family or friends; 42
(29.8%) own will, 12 (8.5%) media influence and 6
(4.3%) recommended by doctor. Among the non-cancer
volunteers, CAM users expected CAM to improve
immune function (n = 79, 61.7%), general wellbeing (n
= 20, 15.7%) and a small proportion expected CAM to
prevent cancer (n = 8, 6.3%). On the other hand, the
cancer patient cohort used CAM with the expectations
that it would cure cancer (n = 1, 0.7%), halt cancer pro-
gression (n = 1, 0.7%), improve symptoms (n = 6, 4.1%),
and 6 patients used it as a complementary to conven-
tional treatments. When asked if they thought CAM
was effective, the majority of CAM users (n = 93, 66.5%)
either agreed or strongly agreed. Only 4 participants
reported negative effects from CAM use (one constipa-
tion and diarrhoea; one drowsiness; one cough, sweating
and weight gain; one urinary incontinence).
In 359 non-users, reasons for not using CAM were
reported to be: did not have enough information about
it (n = 150, 50.2%), no interest (n = 64, 21.4%), did not
believe in it (n = 38, 12.7%), never needed it (n = 14,
4.7%), too expensive (n = 12, 4%), happy with conven-
tional medicine (n = 5, 1.7%) and heard bad comments
about it (n = 4, 1.3%). Interestingly, 151 (46.6%) of the
non-users would like to learn more about CAM.
Among health care professionals, there was a signifi-
cant association between CAM use and professions (p =
0.050). The prevalence of CAM use was the highest
among pharmacist (4/5, 80%), followed by nurses (30/
61, 49.2%), physiotherapists (10/27, 37.0%), and the least
prevalent among doctors (17/59, 28.8%). Longer dura-
tion since qualification was associated with higher likeli-
hood of CAM usage (p = 0.007). There was a high level
of interest among health care professionals with 110
(75.3%) wanting to learn more about CAM.
Communications Between Health Care Professionals and
Patients
In 155 CAM users, 43 (30.1%) voluntarily reported CAM
use to their doctors. The doctors’ response was reported
to be: encouraged to continue (n = 16, 37.2%), advised to
stop (n = 7, 16.3%), neither discouraged nor encouraged
(n = 20, 46.5%), and doctor did not know about CAM (n =
4, 2.8%). Among patients who did not report CAM use
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Variables Number of Participants Number of CAM Users (%) p value (c2)
Total 520 155 (29.8)
Gender <0.001
Male 186 29 (15.6)
Female 330 124 (37.6)
Missing 4 2
Age* 52.5 ± 16.9 49.1 ± 15.5 0.004
†
Ethnicity 0.385
Caucasian 497 149 (30.0)
Non-Caucasian 4 2
Missing 19 4
Educational background <0.001
Primary level 97 11 (11.3)
Secondary level 255 74 (29.0)
Tertiary level 154 66 (42.9)
Missing 13 4
Annual household income 0.001
<€20 000 197 43 (21.8)
€20 000 - €49 999 161 50 (31.1)
€50 000 - €99 999 71 33 (46.5)
>€100 000 12 5 (41.7)
Missing 79 24
Health insurance 0.001
None 71 242 26 (36.6) 52 (21.5)
Public Medical Card
Private Health Insurance 200 76 (38.0%)
Missing 7 1
Religions 0.001
Christian 486 138 (28.4)
Non-Christian 15 11 (73.3)
Missing 19 6
Subgroups 0.369
Non-cancer volunteers 301 93 (30.9)
Cancer patients 219 62 ((28.3)
Breast 81 27 (33.3) 0.667
Colorectal 23 4
Lymphoma 17 6
Leukaemia 13 3
Prostate 12 3
Lung 12 2
Ovarian 12 5
Melanoma 12 6
Head & Neck 7 0
Oesophagus 5 1
Kidney 5 1
Brain 4 1
Cervix 3 1
Stomach 3 0
Testicle 2 0
Urinary bladder 2 0
Non-melanoma skin 2 1
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tors. The majority of patients did not mention CAM use
because the doctor never asked (n = 47, 34.6%), some
thought that the doctor would not understand (n = 5,
3.7%), or would disapprove (n = 8, 5.9%).
From the health care professionals perspective, when
asked about their responses to patients regarding CAM
use, 26 (17.2%) reported that they would encourage to
continue, 5 (3.3%) advise to stop, 92 (60.9%) neither dis-
courage nor encourage. Of these, 58 (38.2%) have been
asked about CAM during consultations in the previous
6 months. A large proportion of health care profes-
sionals (n = 68, 45.9%) thought they would ask patients
about CAM use, while 57 (38.8%) would recommend
CAM to patients. Health care professionals who used
C A Mw e r em o r el i k e l yt or e c o m m e n dC A Mt ot h e i r
patients (p = 0.001).
Health Care Professionals’ Knowledge on CAM
Health care professionals were asked to self-rate their
knowledge on CAM. With regards to having adequate
knowledge, 1 strongly agreed, 22 (14.4%) agreed, 40
Table 1 Characteristics of patient participants (Continued)
Pancreatic 1 1
Myeloma 1 0
Missing 2 0
HADS
High anxiety score (≥11) 44 13 (29.5) 0.350
Low anxiety score (<11) 333 112 (33.6)
Missing 143 30
High depression score (≥11) 13 3 (23.1) 0.328
Low depression score (<11) 386 128 (33.2)
Missing 121 24
Karnofsky score 0.493
80 - 100 106 33 (31.1)
50 - 70 36 7 (19.4)
0 - 40 6 1 (16.7)
Missing 76 24
* mean ± standard deviation
† student’s t-test
Table 2 Characteristics of health care professional participants
Variables Number of Participants Number of CAM Users (%) p value (c2)
Total 156 62 (39.7)
Gender 0.001
Male 38 7 (18.4)
Female 118 55 (46.6)
Age* 31.1 ± 7.3 33.3 ± 8.6 0.001
†
Ethnicity 0.211
Caucasian 136 56 (41.2)
Non-Caucasian 18 5
Missing 1 1
Professions 0.050
Doctors 59 17 (28.8)
Nurses 61 27 30 (49.2)
Physiotherapists 27 10 (37.0)
Pharmacists 5 4 (80.0)
Occupational therapists 2 0
S&L therapists 2 1
* mean ± standard deviation
† student’s t-test
S&L therapists, speech and language therapists
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strongly disagreed. When asked if they were up to date
with the best available evidence on CAM use, none
strongly agreed, 5 agreed, 27 (17.5%) undecided, 83
(53.9%) disagreed and 39 (25.3%) strongly disagreed.
Five questions based on level 1a evidence were
designed to assess health care professionals’ knowledge
on the evidence-based CAM practices including: the
role of acupuncture in chemotherapy-induced nausea
and vomiting; Chinese herbal medicine for side-effects
of chemotherapy; antioxidant for the prevention of lung
cancer; oral fish oil for the treatment of cancer cachexia
and ginger as an effective anti-emetic remedy. The
answers provided are summarised in Table 5. The
majority were undecided on all five questions highlight-
ing the lack of knowledge.
Discussion
In this study, we surveyed the prevalence of CAM use in
three distinctive populations and investigated the preva-
lence, predictive factors, knowledge of and attitudes
toward CAM use. The communication on CAM
between health care professionals and cancer patients
was explored.
One of the strengths of this study is the recruitment
process. Participants were approached and invited to
complete the questionnaires, instead of using mailed-
questionnaire method. With the assistance of nurse
coordinators, the response rate of our study was 100%
among patients who were invited to participate. This
eradicates selection bias inherently associated with most
mail-based study design as patients who use CAM are
more inclined to participate. One might argue that the
prevalence rate of CAM use in this study may not be a
true reflection of the entire population as participants
were accrued from the hospital setting. However, the
prevalence rate reported here is in keeping with pre-
vious large scale population surveys [2,21-23]. Further-
more, patients (cancer or non-cancer) and visitors
included in this study are a representative group of indi-
viduals that hospital-based health care workers interact
with on a daily basis and are therefore clinically relevant.
In our study, the prevalence of CAM use is high in all
groups of participants, intriguingly, the highest among
health care professionals. This would reflect the growing
rates of CAM use and it is an encouraging finding as
CAM becomes more acceptable in the society. There is
no difference in CAM use between cancer patients and
non-cancer volunteers, which is not consistent with pre-
vious reports [5,22-26]. This may be explained by the
inclusion of patients suffering from chronic disorders
other than cancer in the non-cancer volunteer cohort.
Factors associated with increased CAM use such as
female gender, younger age, higher socioeconomic status
and private health insurance shown in our study are
consistent with previous data [4,5,27,28]. Interestingly,
patients with higher anxiety or depression score, more
advanced disease stage and poorer performance status
Table 3 Types of CAM used
Types of CAM Used Number of Users (%)
Natural supplements 83 (53.9)
Vitamins 78 (50.6)
Green tea 62 (40.3)
Massage therapy 51 (33.1)
Herbal remedies 50 (30.5)
Acupuncture 40 (26.1)
Yoga 35 (22.7)
Homeopathy 26 (16.9)
Chinese herbal medicine 25 (16.2)
Chiropractic 20 (13.0)
Meditation 15 (9.7)
Energy healing 14 (9.1)
Spiritual practice 13 (8.5)
Music/art therapy 12 (7.8)
Tai Chi 10 (6.5)
Psychotherapy 8 (5.2)
Hypnotherapy 7 (4.5)
Biofeedback 2 (1.3)
Others (Neuro Linguistic Programming) 1 (0.6)
Table 4 Univariate and multivariate analyses of factors predictive of CAM use
Univariate Multivariate Binary Logistic Regression
Variables p value Likelihood Ratio 95% Confidence Interval p value
Female gender < 0.001 3.703 2.251-6.094 < 0.001
Younger age 0.004 - NS
Higher educational background <0.001 - NS
Higher annual household income 0.001 - NS
Private health insurance 0.001 1.670 1.106-2.521 0.015
Non-Christian <0.001 10.587 3.000-37.359 <0.001
NS, not significant.
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v i o u s l yr e p o r t e dh i g h e rp r e v a l e n c eo fC A Mu s ea m o n g
cancer patients with poorer prognosis [9]. The authors
suggested that this may be due to patients resorting to
non-conventional therapy when less hope of cure is
given by the physicians. In contrast, other studies have
demonstrated that CAM use is not associated with more
advanced disease stage [29-31]. This may be related to
the complexity of underlying psychological and beha-
vioural mechanisms influencing the use of CAM in can-
cer patients such as attitude, family support and coping
behaviour as have been shown by previous reports
[32,33].
The most commonly used CAM is orally ingested
agents such as natural supplements, vitamins, green tea
and herbal remedies. This further highlights the impor-
tance of documentation of the intake of these sub-
stances as part of routine clerking and assessment of
patients in order to avoid potential drug-herb-vitamin
interactions particularly in patients undergoing chemo-
or hormonal therapy. As demonstrated by our study,
most patients do not inform their doctors about CAM
use, mainly because the doctors never ask, or are per-
ceived to be lack of CAM knowledge or disapproving.
Therefore the initiatives to elicit CAM usage through
history taking may be effective in obtaining such
information.
There are numerous reports expressing communica-
tion gaps between health care professionals and patients
on CAM. This is possibly related to the suboptimal evi-
dence-based knowledge on these therapies but none of
these studies had addressed this in detail [4,5,28,34-36].
To our knowledge, this is the first study that includes
both health care professionals’ attitudes toward CAM
use in oncology and an assessment of their knowledge
on these therapies. There is a significant discrepancy
comparing patients and health care professionals’
reported experience toward CAM. While only 8 of 155
CAM users were asked by their doctors about CAM
use, a much higher proportion (45.9%) of health care
professionals thought they would ask patients about its
use. Similarly, only 17.2% of health care professionals
would encourage patients to continue CAM, which is
markedly different from experience reported by patients
that 37.2% of doctors encouraged them to continue
CAM when consulted.
When asked about their knowledge on CAM, the
majority of health care professionals thought they did
not have adequate knowledge (58.8%) nor were up to
date with the best available evidence (79.2%) on CAM
use. This is evident from answers provided by health
care professionals to the five evidence-based CAM ques-
tions. Up to 80% were unsure of the roles of the afore-
mentioned CAM practices in cancer-related scenarios,
thereby not being able to advise patients regarding the
benefits, limitations and even potential harms.
The findings of this study have major implications for
undergraduate education. We demonstrated a high pre-
valence of CAM use in our study population consisting
of cancer and non-cancer patients as well as health care
workers. Despite the lack of awareness and knowledge
on CAM, health care professionals expressed a high
level of interest in CAM education. Until recently few
allopathic medical students worldwide would have been
exposed to the teaching of CAM. In recognition of the
growing needs for medical graduates that have at least
basic understanding of CAM in order to make appropri-
ate referrals as part of integration of CAM into conven-
tional medicine; several countries have incorporated
CAM into undergraduate curricula such as the United
States of America (USA), Finland, Germany, Japan,
Canada, the Netherlands and Switzerland. Notably in
Finland acupuncture has been part of the undergraduate
curriculum since 1975. According to the worldwide
review on CAM published by the World Health Organi-
zation, the majority of medical schools in the USA offer
Table 5 Distribution of answers provided by health care professionals on evidence-based practices of CAM in cancer
Numbers of Answers (%)
Questions Strongly
Agree
Agree Undecided Disagree Strongly
Disagree
There is evidence that acupuncture is effective in reducing first day vomiting after
chemotherapy.
1 (0.6) 19
(12.3)
128 (82.6) 5 (3.2) 2 (1.3)
There is evidence that Chinese herbs decrease side-effects in patients treated with
chemotherapy.
1 (0.6) 11
(7.1)
132 (85.7) 8 (5.2) 2 (1.3)
There is evidence to support recommending antioxidant vitamins such as a-tocopherol,
beta-carotene or retinol to prevent lung cancer.
01 2
(7.8)
127 (82.5) 9 (5.8) 6 (3.9)
There is evidence to support the use of oral fish oil for the management of cancer
cachexia.
01 8
(11.7)
126 (81.8) 8 (5.2) 2 (1.3)
There is evidence that ginger has a potential role as an antiemetic herbal remedy. 10 (6.5) 29
(18.8)
109 (70.8) 4 (2.6) 2 (1.3)
Bold fonts indicate the correct answers according to the best available evidence.
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have been encouraged to attend courses that enable
them to incorporate homeopathy into practices. In Ger-
many, medical schools are required to test students’
knowledge of CAM. In Australia, acupuncturists form a
part of the multidisciplinary management of patients in
the public health sector. The British Medical Association
recommends incorporating CAM into undergraduate
curriculum and making accredited postgraduate training
available [37]. University of Southampton commenced
education on CAM as part of the Special Study Module
(SSM) out of students’ request [38]. As part of the Pro-
fessionalism curriculum, CAM SSM has been made
available at the National University of Ireland Galway
for the last 2 years. The potential for incorporating
CAM as part of a compulsory undergraduate curriculum
remains to be evaluated.
Nevertheless there are some limitations to our study.
The survey was carried out in a single institution invol-
ving generally defined populations of cancer patients,
non-cancer volunteers and health care professionals.
While further studies may be warranted to investigate
the attitudes toward CAM in more specifically defined
populations, the present study produced useful informa-
tion on the overall prevalence of CAM use. The non-
cancer volunteer cohort was accrued from the hospital
environment, which may not be truly reflective of the
general population. Furthermore, the questionnaire used
in this study did not address the use of CAM within a
specific time period or specifically in relation to cancer.
Conclusions
This survey demonstrates a high prevalence of CAM use
among patients and health care professionals. Increased
awareness of CAM use and potential drug-herb-vitamin
interactions is critical for optimal patient care in oncol-
ogy. The incorporation of CAM education into under-
graduate medical curriculum may improve health care
professionals’ knowledge on CAM, thereby improving
doctor-patient communication.
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